Real-World data on ribociclib for breast cancer: what happens outside clinical trials?
NCT ID NCT07243002
First seen Nov 21, 2025 · Last updated May 20, 2026 · Updated 20 times
Summary
This study looks at how well the drug ribociclib works for people with early-stage breast cancer when used in regular medical practice. Researchers will track 3,000 patients to see if the cancer comes back and how patients feel about their treatment. The goal is to understand real-world effectiveness and side effects beyond controlled trial settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGLondon, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.